COMPARATIVE EFFICACY OF RITUXIMAB AND METHOTREXATE MONOTHERAPY IN STANDARD DOSES IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (PRELIMINARY RESULTS)
https://doi.org/10.15690/vsp.v11i1.130
Abstract
This article contains results of the comparative study of rituximab and methotrexate efficacy in children with systemic juvenile idiopathic
arthritis. 115 patients aged 2 to 16 years were enrolled in the study, main group consisted of 75 patients receiving rituximabe, and 40 patients in control group receiving methtrexate. The efficacy of rituximab treatment was significantly higher, than that of methotrexate in standard doses. Evident improvement in patients receiving rituximab was seen already after 12 weeks of treatment. During this period in 90% of patients life-threatening systemic manifestations were relieved, acuteness of articular syndrome was decreased, lab parameters normalized. Within 24 weeks there was a significant decrease of the disease activity, improvement of joint functional activity and decrease in disability degree. 25% of patients were diagnosed with inactive stage of the disease. Methotrexate treatment had virtually no effect on systemic manifestations, there were still relapses seen in patients (including those of life-threatening conditions), persistence of active arthritis, high activity in lab parameters and disability progression were also seen against its background.
Key words: systemic idiopathic juvenile arthritis, rituximab, methotrexate, children.
arthritis. 115 patients aged 2 to 16 years were enrolled in the study, main group consisted of 75 patients receiving rituximabe, and 40 patients in control group receiving methtrexate. The efficacy of rituximab treatment was significantly higher, than that of methotrexate in standard doses. Evident improvement in patients receiving rituximab was seen already after 12 weeks of treatment. During this period in 90% of patients life-threatening systemic manifestations were relieved, acuteness of articular syndrome was decreased, lab parameters normalized. Within 24 weeks there was a significant decrease of the disease activity, improvement of joint functional activity and decrease in disability degree. 25% of patients were diagnosed with inactive stage of the disease. Methotrexate treatment had virtually no effect on systemic manifestations, there were still relapses seen in patients (including those of life-threatening conditions), persistence of active arthritis, high activity in lab parameters and disability progression were also seen against its background.
Key words: systemic idiopathic juvenile arthritis, rituximab, methotrexate, children.
About the Authors
E. I. Alexeeva
Scientific Centre of Children’s Health RAMS, Moscow;
Sechenov First Moscow Medical University
Russian Federation
Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS
Russian Federation
Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS
S. I. Valieva
Scientific Centre of Children’s Health RAMS, Moscow
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children’s Health RAMS, Moscow
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Centre of Children’s Health RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children’s Health RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children’s Health RAMS, Moscow
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Centre of Children’s Health RAMS, Moscow
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Centre of Children’s Health RAMS, Moscow;
Sechenov First Moscow Medical University
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E. Juvenile idiopathic arthritis. In Cassidy J. T., Petty R. E. eds. Textbook of pediatric rheumatology, 5th edn. Philadelphia: WB Saunders, 2005.
2. Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита // Вопросы современной педиатрии. — 2009; 8 (5): 14–25.
3. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общей ред. акад. РАМН, проф. А. А. Баранова. — М., 2007. — 368 с.
4. Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis // Rheumatism. — 2002; 49 (1): 20–24.
5. Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis // J. Pediatr. — 1998; 133: 179–180.
6. Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis // Arch. Dis. Child. — 2003; 88: 197–200.
7. Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis // Therapy. — 1999; 81: 766–772.
8. Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group // N. Engl. J. Med. — 1992; 326: 1043–1049.
9. Woo P., Southwood T. R., Prieur A. M. et al. Randomized, pla cebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthr. Rheum. — 2000; 43 (8): 1849–1857.
10. Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate // Arthritis Rheum. — 2004; 50: 2191–2201.
11. Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2009; 27 (6): 1047–1053.
12. Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate // J. Rheumatol. — 2004; 31 (1): 179–182.
13. Woo P., Southwood T. R., Prieur A. M. et al. Randomised placebocontrolled crossover trial with low dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthritis Rheum. — 2000; 43: 1849–1857.
14. Beukelman T., Patkar N. M., Saag K. G. et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features // Arthritis Care Res (Hoboken). — 2011; 63: 465–482.
15. Noorchashm H., Noorchashm N., Kern J., Rostami S. Y., Barker C. F., Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice // Diabetes. — 1997; 46: 941–946.
16. Chan O. T., Hannum L. G., Haberman A. M., Madaio M. P., Shlom chik M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus // J. Exp. Med. — 1999; 89: 1639–1648.
17. Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis // J. Immunol. — 2001; 167: 1072–1080.
18. O’Neill S. K., Shlomchik M. J., Glant T. T. et al. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis // J. Immunol. — 2005; 174: 3781–3788.
19. Anolik J. H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus // Arthritis Rheum. — 2004; 50: 3580–3590.
20. Wallace C. A., Sherry D. D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis // J. Rheumatol. — 1992; 19: 1604–1607.
21. Reiff A., Shaham B., Wood B. P., Bernstein B. H., Stanley P., Szer I. S. High dose methotrexate in the treatment of refractory
22. juvenile rheumatoid arthritis // Clin. Exp. Rheumatol. — 1995; 13: 113–118.
23. Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs // Inflamm. Res. — 1996; 45: S91–95.
24. Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children // Clin. Rheumatol. — 1998; 17: 505–510.
25. SmolenKeystone E. C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis // Ann. Rheum. Dis. — 2007; 66: 143–150.
26. Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries // Ann. Rheum. Dis. — 2011; 70 (9): 1575–1580.
27. Edwards J. C., Szczepanski L., Szechinski J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. — 2004; 350: 2572–2581.
28. Emery P., Fleischmann R., Filipowicz-Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial // Arthritis Rheum. — 2006; 54: 1390–1400.
29. Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks // Arthritis Rheum. — 2006; 54: 2793–2806.
30. van Vollenhoven R. F., Emery P., Bingham C. O. et al. Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials // J. Rheumatol. — 2010; 37: 558–567.
31. Rubbert-Roth A., Tak P. P., Zerbini C. et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) // Rheumatology (Oxford). — 2010; 49: 1683–1693.
32. Emery P., Deodhar A., Rigby W. F. et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) // Ann Rheum Dis. — 2010; 69: 1629–1635.
33. Tak P. P., Rigby W. F., Rubbert-Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial // Ann. Rheum. Dis. — 2011; 70: 39–46.
34. Loveless J. E., Olech E., Pritchard C. et al. An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL) // Arthritis Rheum. — 2009; 60: S1660.
35. Kuek A., Hazleman B. L., Gaston J. H. et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab // Rheumatology (Oxford). — 2006; 45: 1448–1449.
36. Foeldvari I., Bica B., Dedeoglu F. Efficacy of rituximab in rf factor negative juvenile idiopathic arthritis [FRI0450] // Ann. Rheum. Dis. — 2009; 68 (Suppl. 3): 502.
37. Алексеева Е. И., Валиева С. И., Бзарова Т. М. и др. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного артрита // Вопросы современной педиатрии. — 2009; 8 (5): 19–30.
38. Alexeeva E. I., Valieva S. I., Bzarova T. M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis // Clin Rheumatol. — 2011; 9 (30): 1163–1172
Review
For citations:
Alexeeva E.I., Valieva S.I., Denisova R.V., Bzarova T.M., Isaeva K.B., Mitenko E.V., Sleptsova T.V., Chistyakova E.G. COMPARATIVE EFFICACY OF RITUXIMAB AND METHOTREXATE MONOTHERAPY IN STANDARD DOSES IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (PRELIMINARY RESULTS). Current Pediatrics. 2012;11(1):37-45. (In Russ.) https://doi.org/10.15690/vsp.v11i1.130
Views:
777
Email this article 
